The Partnering Agreements with Emergent BioSolutions report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies. Read the full story

Big biotech, Emergent BioSolutions has signed a contract with the National Institute of Allergy and Infectious Diseases to develop a dry formulation of NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant). Read the full story

Emergent BioSolutions announced a biotech licensing agreement for the joint development and commercialization of Emergent’s preclinical bi-specific antibody, ES414, targeting prostate cancer. Read the full story

Emergent BioSolutions announced a biotech deal with Centers for Disease Control and Prevention has exercised options under contract 200-2012-52242 for the supply of Vaccinia Immune Globulin Intravenous into the U.S. Strategic National Stockpile. Read the full story

Valneva has signed two pharma deal granting Emergent BioSolutions and its affiliates research and commercialization rights for new and existing vaccine candidates using Valneva’s EB66 cell line. Read the full story

M&A news : Big biotech company, Emergent BioSolutions will acquire Cangene in an all-cash transaction valued at US$222 million Read the full story

Cangene agreed for an m&a by Emergent BioSolutions in an all-cash transaction valued at US$222 million. Read the full story

Read the full story